Elecsys fsh reagent kit

We also evaluated AMH and FSH as secondary outcomes. FSH concentration was measured with an automated electrochemiluminescence immunoassay using the Elecsys FSH reagent kit and the Roche Elecsys immunoassay analyser (Roche Diagnostics, Indianapolis, IN, USA) from a blood sample collected on the third day of the menstrual cycle at the MGH Core Laboratory (28 (link)). Serum AMH was measured from blood samples that were collected during the follicular phase of IVF cycle using the Ansh Labs ultra-sensitive AMH/mullerian-inhibiting substance enzyme linked immunosorbent assay at Mayo Clinic Department of Laboratory Medicine and Pathology (Rochester, MN) before January 2018, and later, using the Elecsys AMH immunoassay by Roche Diagnostics (Roche Diagnostics GmbH) at the Brigham and Women’s Hospital Laboratory of Pathology in Boston(29 (link)).

Ovarian reserve measures included AFC and circulating levels of day-3 FSH and AMH. All women participating in the study underwent an evaluation of ovarian AFC through transvaginal ultrasonography by one of the MGH reproductive endocrinology and infertility physicians in early follicular phase of an unstimulated cycle. No fertility medications were used in the cycle preceding the ultrasonographic determination of the AFC. Women participating in the study provided several blood samples (5 mL) during the study. The levels of day 3 FSH (third day of the menstrual cycle) and AMH were measured in collected serum samples with an automated electrochemiluminescence immunoassay using the Elecsys FSH reagent kit and the Roche Elecys immunoassay analyzer (Roche Diagnostics, Indianapolis, IN, USA) at the MGH Core Laboratory. For women with more than one measure of AFC, FSH or AMH, only the first measure was used in the analysis. AFC, day 3 FSH and AMH levels were considered the outcomes variables and were assessed continuously.